52662-76-7

Usage

InChI:InChI=1/C7H15N3O/c8-10-7(11)9-6-4-2-1-3-5-6/h6H,1-5,8H2,(H2,9,10,11)

Upstream product

• 766-93-8 N-cyclohexylformamide 
• 4998-76-9 cyclohexylamine hydrochloride 
• 698-90-8 N'-cyclohexylurea 
• 56379-88-5 cyclohexylcarbamic acid phenyl ester 
• 70243-23-1 N-cyclohexyl-1H-benzo[d][1,2,3]triazole-1-carboxamide 
• 108-91-8 cyclohexylamine 
• 3173-53-3 Cyclohexyl isocyanate 
• 35580-95-1 N-Cyclohexyl-carbamidsaeure-(2-hydroxyphenyl)-ester 

Downstream Products

• 1445852-06-1 C₁₄H₁₈N₆O₂ 
• 1428369-95-2 C₂₃H₃₄N₆O₃ 
• 301203-03-2 N-cyclohexyl-2-(4-methoxybenzylidene)hydrazinecarboxamide 
• 1416358-58-1 C₂₂H₃₂ClN₃O 
• 1416358-56-9 C₂₅H₃₀ClN₃O 
• 1416358-53-6 C₂₄H₂₈ClN₃O 
• 1416358-51-4 C₂₄H₂₉N₃O 
• 64412-56-2 4-benzyl-3-(4-chloro-phenyl)-4,5-dihydro-pyrazole-1-carboxylic acid cyclohexylamide 
• 1416358-49-0 C₂₃H₂₇N₃O 

Relevant academic research and scientific papers

Insight on a new indolinone derivative as an orally bioavailable lead compound against renal cell carcinoma

A series of novel 3-indolinone-thiazolidinones and oxazolidinones 4a-k was synthesized via molecular hybridization approach and sequentially evaluated to explore its cytotoxic activity. The cytotoxicity screening pointed toward the N-cyclohexyl thiazolidinone derivative 4f that revealed promising renal cytotoxicity against CAKI-1 and UO-31 renal cancer cell lines with IC50 values 4.74 and 3.99 μM, respectively, which were comparable to those of sunitinib along with good safety threshold against normal renal cells. Further emphasis on compound 4f renal cytotoxicity was achieved via different enzyme assays and CAKI-1 and UO-31 cell cycle analysis. The results were supported by in silico studies to explore its physicochemical, pharmacokinetic and drug-likeness properties. Finally, compound 4f was subjected to an in vivo pharmacokinetic study through two different routes of administration showing excellent oral bioavailability. This research represents compound 4f as a promising candidate against renal cell carcinoma.

Novel synthesis and biological evaluations of N,N’-disubstituted-3,6-bis(substitutedphenyl)-1,2,4,5-tetrazine-1,4-dicarboxamide

A series of novel N,N’-disubstituted-3,6-bis(substitutedphenyl) -1,2,4,5-tetrazine-1,4-dicarboxamides were prepared using the intermolecular cyclization reaction of N-substituted-N’-(α-chloro-substitutedbenzylidene) hydrazinecarboxamide and triethylamine by the modification of solvent polarity. The structures of all the new compounds were characterized by IR, 1H-NMR, MS and elemental analysis. Their cytostatic effects were screened in vitro by the SRB method for A-549 cell and the MTT method for P-388 cell. The results showed that several compounds demonstrate potential antitumor activities against P-388. The substituents have clearly effect on their antitumor activity.

Highly Regioselective Carbamoylation of Electron-Deficient Nitrogen Heteroarenes with Hydrazinecarboxamides

The use of hydrazinecarboxamides as a new class of carbamoylating agents has been established through the dehydrazinative Minisci reaction of electron-deficient nitrogen heteroarenes. A wide range of electron-deficient nitrogen heteroarenes, including isoquinoline, quinoline, pyridine, phenanthridine, quinoxaline, and phthalazine, underwent copper/acid-catalyzed oxidative carbamoylation with hydrazinecarboxamide hydrochlorides to afford structurally diverse nitrogen-heteroaryl carboxamides as single regioisomers in moderate to excellent yields. The functional group tolerance was substantially demonstrated in the direct carbamoylation of quinine obviating multistep sequences involving protecting groups and prefunctionalization of the heterocycle.

Novel 1-acyl-4-substituted semicarbazide derivatives of primaquine-synthesis, cytostatic, antiviral and antioxidative studies

A series of novel 1,4-substituted semicarbazides 5a-g with a primaquine moiety bridged by a carbonyl group at position 1 and a cycloalkyl, aryl, benzyloxy or hydroxy substituent at position 4 were prepared and biologically evaluated. The synthetic pathway

Scaffold hopping strategy toward original pyrazolines as selective CB 2 receptor ligands

In line of a scaffold hopping strategy of pyrazole structures, especially known as potent CB2 receptor antagonists, we exploited an original and convergent synthesis of a new class of C4-benzyl pyrazolines and derivatives from readily available

N6-cyclopentyl-2-(3-phenylaminocarbonyltriazene-1-yl)adenosine (TCPA), a very selective agonist with high affinity for the human adenosine A1 receptor

Four subtypes of adenosine receptors are currently known, that is, A1, A2A, A2B, and A3 receptors. Interestingly, quite substantial species differences exist especially between human and rat A3 receptors. As a result, ligands such as CCPA, which are very selective for the rat A1 receptor versus the human A3 receptor, are substantially less selective when the human A1 and A3 receptors are compared. New 2-substituted and 2,N6-disubstituted adenosines were synthesized, and their affinities for the human adenosine A1, A2A, A2B, and A3 receptors were determined. Although large substituents on the C2-position are generally thought to yield adenosine A2A receptor selective ligands, the reported series of 2-triazeno-substituted adenosines had a very high affinity for the A1 receptor. For example, 2-(3-phenylaminocarbonyltriazene-1-yl)adenosine had an affinity of 6.1 ± 1.3 nM for the human adenosine A1 receptor. Introduction of a diphenethyl substituent at the N6-position of this compound resulted in a high-affinity agonist, 3.1 ± 0.9 nM, for the human adenosine A1 receptor with 316- and 45-fold selectivity versus the human A2A and human A3 receptors, respectively. The most selective, high-affinity human adenosine A1 receptor agonist was the disubstituted compound N6-cyclopentyl-2-(3-phenylaminocarbonyltriazene-1-yl)adenosine (TCPA). TCPA had an affinity of 2.8 ± 0.8 nM for the human adenosine A1 receptor and was 75-fold and 214-fold selective versus the human A2A and human A3 receptors, respectively. In addition, TCPA was a full agonist and inhibited the forskolin-induced cAMP production of CHO cells stably transfected with the human adenosine A1 receptor with an IC50 of 1.5 ± 0.5 nM.

Carbazoyl derivatives

A carbazoyl derivative of the general formula: (wherein, R1brepresents a bond, alkylene group of from 1 to 6 carbon atom(s) or alkenylene group of from 2 to 6 carbon atoms,R2brepresents a carbocyclic or heterocyclic ring unsubstituted or substituted by from one to three halogen atom(s), hydroxy group, nitro group, amino group, alkyl or alkoxy group of from 1 to 4 carbon atom(s), 3-aminoureido group, phenoxy group or acylamino group of from 2 to 5 carbon atoms, or R1btogether with R2b, represents an alkyl group of from 1 to 12 carbon atom(s) unsubstituted or substituted by 3-aminoureido group,R3brepresents (1) a hydrogen atom,(2) an alkyl group of from 1 to 6 carbon atom(s) or, (3) a phenyl or benzyl group unsubstituted or substituted by from one to three halogen atom, alkyl or alkoxy group of from 1 to 4 carbon atom(s), hydroxy group or nitro group,Xbrepresents a bond or imino gorup,with the proviso that the compounds wherein the groups shown by Xb-R1b-R2brepresent a phenyl group, 4-aminophenyl gorup, anilino group and 2-thienyl group and the groups shown by R3brepresent a hydrogen atom, are excluded.),or an acid addition salt thereof possesses inhibitory activity on Maillard reaction, and therfore is useful for treating and/or prevention of several diabetic complications and deseases induced by aging.